Increased Prevalence of Liver Fibrosis and HIV Viremia among Patients with HIV, HBV, and Tuberculosis in Botswana
People with concomitant human immunodeficiency virus (HIV) and tuberculosis (TB) have an increased risk of hepatotoxic reactions due to antiretroviral therapy (ART) and anti-TB therapy (ATT). Concomitant hepatitis B virus (HBV) in these patients may lead to poorer health outcomes. To assess liver enzyme levels and immune response in adults with HIV, HBV, and TB, data from 300 antiretroviral-naïve people living with HIV (PLWHIV) were analyzed. The prevalence of HIV/HBV (cHIV/HBV) and HIV/TB (cHIV/TB) was 28% (95% CI: 23.0-33.4) and 10% (95% CI: 6.8-14.0), respectively. HIV/HBV/TB (cHIV/HBV/TB) prevalence was 5.3% (95% CI: 3.1-8.5). There was a statistically significant difference between the groups of participants in HIV viral load (p = 0.004), hemoglobin levels (p = 0.025), and body mass index (p = 0.011). A larger proportion of cHIV/HBV/TB participants (37.5%) had an aspartate aminotransferase to platelet ratio index (APRI) score ≥0.5 (p = 0.013), a lower cutoff for significant liver fibrosis. Immunological non-responders (CD4+ T-cell count <20% gain and HIV viral load <400 copies/mL at 6 months) were observed in all groups except those with cHIV/TB. Our findings support the need to screen for infections that could cause excessive liver damage prior to ATT or ART initiation, such as HBV.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Pathogens (Basel, Switzerland) - 9(2020), 11 vom: 14. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Phinius, Bonolo B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Africa |
|---|
| Anmerkungen: |
Date Revised 01.12.2020 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/pathogens9110950 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317698524 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317698524 | ||
| 003 | DE-627 | ||
| 005 | 20231225163817.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/pathogens9110950 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1058.xml |
| 035 | |a (DE-627)NLM317698524 | ||
| 035 | |a (NLM)33202597 | ||
| 035 | |a (PII)E950 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Phinius, Bonolo B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increased Prevalence of Liver Fibrosis and HIV Viremia among Patients with HIV, HBV, and Tuberculosis in Botswana |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.12.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a People with concomitant human immunodeficiency virus (HIV) and tuberculosis (TB) have an increased risk of hepatotoxic reactions due to antiretroviral therapy (ART) and anti-TB therapy (ATT). Concomitant hepatitis B virus (HBV) in these patients may lead to poorer health outcomes. To assess liver enzyme levels and immune response in adults with HIV, HBV, and TB, data from 300 antiretroviral-naïve people living with HIV (PLWHIV) were analyzed. The prevalence of HIV/HBV (cHIV/HBV) and HIV/TB (cHIV/TB) was 28% (95% CI: 23.0-33.4) and 10% (95% CI: 6.8-14.0), respectively. HIV/HBV/TB (cHIV/HBV/TB) prevalence was 5.3% (95% CI: 3.1-8.5). There was a statistically significant difference between the groups of participants in HIV viral load (p = 0.004), hemoglobin levels (p = 0.025), and body mass index (p = 0.011). A larger proportion of cHIV/HBV/TB participants (37.5%) had an aspartate aminotransferase to platelet ratio index (APRI) score ≥0.5 (p = 0.013), a lower cutoff for significant liver fibrosis. Immunological non-responders (CD4+ T-cell count <20% gain and HIV viral load <400 copies/mL at 6 months) were observed in all groups except those with cHIV/TB. Our findings support the need to screen for infections that could cause excessive liver damage prior to ATT or ART initiation, such as HBV | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Africa | |
| 650 | 4 | |a Botswana | |
| 650 | 4 | |a hepatitis B virus | |
| 650 | 4 | |a human immunodeficiency virus | |
| 650 | 4 | |a tuberculosis | |
| 700 | 1 | |a Anderson, Motswedi |e verfasserin |4 aut | |
| 700 | 1 | |a Bhebhe, Lynnette |e verfasserin |4 aut | |
| 700 | 1 | |a Baruti, Kabo |e verfasserin |4 aut | |
| 700 | 1 | |a Manowe, Godiraone |e verfasserin |4 aut | |
| 700 | 1 | |a Choga, Wonderful T |e verfasserin |4 aut | |
| 700 | 1 | |a Mupfumi, Lucy |e verfasserin |4 aut | |
| 700 | 1 | |a Mbangiwa, Tshepiso |e verfasserin |4 aut | |
| 700 | 1 | |a Mudanga, Mbatshi |e verfasserin |4 aut | |
| 700 | 1 | |a Moyo, Sikhulile |e verfasserin |4 aut | |
| 700 | 1 | |a Marlink, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Blackard, Jason T |e verfasserin |4 aut | |
| 700 | 1 | |a Gaseitsiwe, Simani |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pathogens (Basel, Switzerland) |d 2011 |g 9(2020), 11 vom: 14. Nov. |w (DE-627)NLM22512761X |x 2076-0817 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2020 |g number:11 |g day:14 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/pathogens9110950 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2020 |e 11 |b 14 |c 11 | ||